Acerus Pharmaceuticals Corporation (ASP.TO) Research

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical firm dedicated to the development, production, marketing, and distribution of medications for men's and women's health. Its marketed products include Natesto, a nasal gel used for testosterone replacement therapy in adult males diagnosed with hypogonadism, and Noctiva, a vasopressin analog indicated for the treatment of nocturia stemming from nocturnal polyuria in adults who awaken at least two times per night to void. The company is also developing a pipeline of products such as Lidbree, a short-acting lidocaine formulation delivered into the vaginal mucosal tissue using a proprietary device; Stendra, a PDE5 inhibitor for treating erectile dysfunction; Tefina, a clinical-stage therapy for female sexual dysfunction; and various Noctiva combination products, which are in pre-clinical development stages for conditions including benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. Furthermore, Acerus utilizes the TriVair technology platform for pulmonary and nasal dosing. Distribution of its products occurs via its salesforce in the United States and Canada, and through a network of international distributors. Founded in 2008, the company operated as Trimel Pharmaceuticals Corporation until changing its name to Acerus Pharmaceuticals Corporation in September 2015. It maintains its headquarters in Mississauga, Canada.

Open Acerus Pharmaceuticals Corporation (ASP.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.